CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for OncoSec Medical Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

OncoSec Medical Inc
820 Bear Tavern Road
Phone: (858) 210-7333p:858 210-7333 EWING, NJ  08628  United States Ticker: ONCSONCS

Filed for Bankruptcy on 6/14/2023
Case #23-15178, filed in the U.S. Bankruptcy Court for the District of New Jersey (Trenton)(Chapter 7)

Business Summary
OncoSec Medical Incorporated is a late-stage immuno-oncology company. The Company is focused on designing, developing and commercializing intra-tumoral DNA-based therapeutics delivered by electroporation (EP) to stimulate and augment anti-tumor immune responses for the treatment of cancers. Its core technology, ImmunoPulse, is a drug-device therapeutic modality platform comprised of an OncoSec Medical System EP device (the OMS EP Device) and a DNA plasmid delivery and application method that enables transient expression of recombinant therapeutic molecules in cells. The OMS EP Device is designed to promote cellular uptake of plasmid DNA injected directly into solid tumors to allow subsequent expression of the encoded therapeutic protein. The OMS EP Device can be adapted to treat different tumor types and consists of an electrical pulse generator and a disposable applicator. Its lead product candidate, tavokinogene telseplasmid (TAVO), is a plasmid encoding human interleukin-12.
(Source: 10-Q)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
1/31/20237/31/2022YesYesYes--

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Chairman of the Board LindaShi 58 12/17/2021 12/17/2021
President, Chief Executive Officer, Director Robert H.Arch 56 10/15/2022 5/2/2022
Chief Financial Officer GeorgeChi 53 2/21/2022 2/21/2022
6 additional Officers and Directors records available in full report.

Business Names
Business Name
OncoSec Medical Australia Pty, Ltd.
OncoSec Medical Inc
OncoSec Medical Inc
4 additional Business Names available in full report.

General Information
Number of Employees: 40 (As of 7/31/2022)
Outstanding Shares: 5,962,652 (As of 5/16/2023)
Shareholders: 42
Stock Exchange: OTC
Federal Tax Id: 980573252


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, March 28, 2024